Company Overview and News

How proptech is changing Hong Kong’s property industry

2018-05-16 scmp
Start-ups in Asia-Pacific have received US$4.8b, or over 60pc of the world’s proptech investments, with Hong Kong and China taking US$3b of that amount

Sun Hung Kai pays HK$25.1 billion for Hong Kong’s costliest residential land at Kai Tak

2018-05-15 scmp
One of the city’s largest land owners won the 14th government tender by paying a record HK$25.1 billion for a plot with gross floor area of 1.42 million sq ft

Kai Tak plot could fetch US$3.25 billion, smashing records for Hong Kong land sales

2018-05-11 scmp
Developers are forming consortiums to spread the financial risk of bidding for a residential site that could fetch an estimated US$3.25 billion

Mico Chung, the upstart Hong Kong developer who aims to join the ‘big boys’ league

2018-05-11 scmp
Once touted as ‘Richard Li’s right-hand man’, does one of Hong Kong’s savviest deal makers have what it takes to found a new property empire to rival that of Henderson or New World?

Canto-pop star Joey Yung buys luxury home in Repulse Bay for estimated US$25 million

2018-05-08 scmp
Hong Kong’s home prices have surged for 24 consecutive months, the longest stretch for a property bull market in a quarter of a century

Sino Land, CSI join forces to win Yau Tong land site, adding even more appeal to former Kowloon industrial area

2018-05-08 scmp
Winning bid not disclosed, but the land premium paid on the site was confirmed at HK$1.515 billion (US$193 million)

Sino Land, CSI join forces to win Yau Tong land site, adding even more appeal to former Kowloon industrial area

2018-05-08 scmp
Winning bid not disclosed, but the land premium paid on the site was confirmed at HK$1.515 billion (US$193 million)

25 Hong Kong and mainland developers bid for Tsing Yi site despite ‘not that ideal’ assessment

2018-04-06 scmp
The tender for a non-industrial site in Tsing Yi attracted 25 bids on Friday, with developers ignoring the site’s location and small size in a sign of hunger for land in the world’s most expensive city.

China stocks rally as consumer, banking firms climb

2018-03-01 thehindubusinessline
China stocks recouped earlier losses to climb by midday Thursday as consumer and banking firms rose, after a private survey showed the country's factory growth rose to a 6-month high in February.

Hong Kong developer Sino Land to give special dividend after core profit rises by 218 per cent

2018-02-28 scmp
One-off gain helps Hong Kong developer offset sharp drop in property sales in July to December period

Hong Kong developers expected to report upbeat half-year results, lifted by project releases, soaring home prices

2018-02-25 scmp
Hong Kong homebuilders are expected to report strong half-year and full-year earnings during the coming weeks as home prices continued to soar and sales of new flats climbed to a decade high.

Hong Kong home prices might surge by 10 per cent this year, says sales head at Henderson 

2018-02-16 scmp
Land and home prices in the city have risen consistently since the fourth quarter of 2016

Kwun Tong residential site attracts 25 bids despite concerns over infrastructure capacity

2018-01-19 scmp
Developers’ enthusiasm for land tenders has shown no signs of easing – a residential site in Hong Kong’s Kwun Tong has attracted stronger than expected interest. But valuers said infrastructure in the region might not be able to support the extra population.

Wharf wins luxury residential site in Kowloon Tong for record price

2018-01-16 scmp
Wharf pays HK$12.45 billion, or HK$28,530 per sq ft for the plot, smashing the previous record of HK$21,016 per sq ft for Kowloon

Hong Kong stocks up for 9th day, close at 10-year high

HONG KONG: Hong Kong stocks rose for a ninth straight session on Friday, aided by strong gains by real estate firms, and the benchmark Hang Seng Index closed at a 10-year high. Chinese appetite for Hong Kong equities, ample cash supply and optimism over share reforms could propel the city's benchmark stock index up as much as 15 percent this year, after an already bullish run in 2017, fund managers and analysts say.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

7h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

8h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

18h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...